Business
Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian. Highlights Progressed clinical development of tecarfarin. Completed the manufacturi
About this update from Cadrenal Therapeutics, Inc.
[{"type":"image","alt":"Cadrenal Therapeutics Inc.","displaySize":"","headline":null,"caption":"Cadrenal Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/39d76876f0bb492d3ae96512360c5747"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/O2jr.ga20FAqxm0lkGKePw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/39d76876f0bb492d3ae96512360c5747","width":300,"height":86}},"lazy":false},{"type":"text","content":"PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian.","length":416,"tagName":"p"},{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Progressed clinical development of tecarfarin.","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Completed the manufacturing of tecarfarin drug product in accordance with current good manufacturing practices (cGMP).","length":118,"tagName":"p"}]},{"val":[{"type":"text","content":"Ongoing activities in support of a single-site U.S. Phase 2 study of tecarfarin in LVAD patients as part of the collaboration agreement with Abbott.","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"Investigator discussions for a potential multi-site Phase 2 study of tecarfarin in dialysis patients already treated with warfarin.","length":131,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":397,"olType":false}]},{"val":[{"type":"text","content":"Expanded Cadrenal’s portfolio through the acquisition of the assets of eXIthera Pharmaceuticals, including its proprietary portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors, in September 2025.","length":219,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The lead asset, frunexian, is a first-in-class, Phase 2-ready IV Factor XIa inhibitor designed for acute care settings where contact activation of coagulatio...